Media Articles Related to Acular PF (Ketorolac Tromethamine Ophthalmic)
A Scientist Shares His Battle to Withdraw From Painkillers
Source: Medscape General Surgery Headlines [2017.01.13]
Travis Rieder spent more than four weeks in hospitals and nearly lost his foot after a van ran a stop sign and struck his motorcycle on Memorial Day weekend in 2015.
Reuters Health Information
Yoga May Ease Pain, Up Function in Chronic Low Back Pain
Source: Medscape NeurologyHeadlines [2017.01.13]
Yoga may improve function and lessen pain in patients with chronic, nonspecific low back pain, a new Cochrane review suggests.
Medscape Medical News
Open-label Placebo Treatment in Chronic Low Back Pain
Source: Medscape Anesthesiology Headlines [2017.01.12]
Can a placebo treatment improve chronic low-back pain--even when the patient is aware that it's a placebo?
Medical News Today: Can yoga help with chronic back pain?
Source: Featured Health News from Medical News Today [2017.01.12]
A new systematic Cochrane review analyzes existing studies on the benefits of yoga for reducing chronic, non-specific lower back pain.
The weather's not to blame for your aches and pains
Source: Arthritis / Rheumatology News From Medical News Today [2017.01.12]
New research from The George Institute for Global Health has revealed the weather plays no part in the symptoms associated with either back pain or osteoarthritis.
Published Studies Related to Acular PF (Ketorolac Tromethamine Ophthalmic)
Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. 
BACKGROUND/AIMS: To evaluate the benefit of adding a nonsteroid agent to an antibiotic/steroid combination after uneventful phacoemulsification, adopting a weekly follow-up, to gain insight into the optimal duration of postoperative treatment and to examine whether risk factors for inflammation exist... CONCLUSION: The addition of ketorolac did not seem to offer any additional benefit in terms of inflammation-related signs. Four weeks appeared as an adequate treatment interval. Special attention should be paid to patients with pseudoexfoliation. Copyright (c) 2010 S. Karger AG, Basel.
Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial. [2010.12]
OBJECTIVE: To determine the level of intraocular penetration of diclofenac sodium and ketorolac tromethamine into the aqueous humour and subretinal fluid. DESIGN: Prospective randomized clinical trial. PARTICIPANTS: Twenty eyes scheduled for retinal detachment surgery and 17 eyes scheduled for cataract surgery... CONCLUSIONS: The concentration in the subretinal fluid of topically applied diclofenac was higher than that of ketorolac; and topical ketorolac penetrated into the aqueous humour better than diclofenac did. This suggests that diclofenac can be used more effectively in events related to posterior segment and ketorolac in anterior segment events.
Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. [2010.05]
PURPOSE: To compare the anti-inflammatory efficacy and subjective tolerability of preservative-free and preserved diclofenac 0.1% and preserved ketorolac 0.5% eye drops for prophylaxis and management of inflammation after cataract surgery. DESIGN: Prospective, randomized, investigator-masked, parallel-group, comparative clinical trial... CONCLUSIONS: Anti-inflammatory efficacy was comparable for all 3 agents. However, preservative-free diclofenac 0.1% eyedrops exhibited a significantly better postoperative subjective and objective tolerability when compared with preserved eyedrops containing ketorolac or diclofenac. Copyright 2010 Elsevier Inc. All rights reserved.
Use of Acular LS in the pain management of keratoconus: a pilot study. [2010.02]
PURPOSE: The purpose of this pilot study was to determine the efficacy of ketorolac tromethamine 0.4% for pain management in conjunction with rigid gas permeable contact lenses in keratoconus. Any potential side effects and complications of this application were examined... CONCLUSIONS: There was no conclusive result as to the efficacy of the ketorolac tromethamine 0.4% vs. the artificial tear solution in the pain management of keratoconus. This could be attributed to a number of physiological and situational factors, as well as small sample size.
Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. [2009.06]
INTRODUCTION: Ketorolac 0.4% administered four times daily (q.i.d.) has long been used safely and effectively for the alleviation of ocular inflamation and pain and the prevention of intraoperative miosis in patients undergoing cataract surgery. Bromfenac ophthalmic solution 0.09% was recently developed as an ocular anti-inflammatory drug with a twice-daily (b.i.d.) dosing regimen. This study was designed to evaluate if b.i.d. dosing with bromfenac 0.09%, in comparison with q.i.d. dosing with ketorolac 0.4%, provides adequate trough nonsteroidal anti-inflammatory drug levels that were effective enough to reduce aqueous prostaglandin (PG) E(2) levels of patients after cataract surgery toward the end of its dosing cycle... CONCLUSIONS: Ketorolac 0.4% maintained significantly higher aqueous concentrations and lowered aqueous PGE(2) levels significantly more than bromfenac 0.09% at trough levels. Ketorolac 0.4% administered q.i.d. may provide a more sustained control of intraocular inflammation and pain than bromfenac 0.09% administered b.i.d.
Clinical Trials Related to Acular PF (Ketorolac Tromethamine Ophthalmic)
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity [Enrolling by invitation]
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye
drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or
decrease its severity. In this study ACULAR will be compared to a placebo (artificial tear).
The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to
severe ROP (grade II and above)by 50%.
Ketorolac in Postoperative Infants: Pharmacokinetics and Safety [Completed]
Infants handle ketorolac differently than adults. Study of handling of this pain medication
given to infants following surgery. Detailed analysis of how the drug is eliminated from age
2 months to 18 months. Compared morphine use in infants who received the drug to the group
getting placebo. Safety testing for kidney and liver function, breathing measured by
continuous oximetry, and any bleeding issues.
Pharmacokinetics of Intranasal Ketorolac in Children [Recruiting]
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that is typically given to both
adults and children by the intravenous (IV) or intramuscular (IM) route for analgesic
purposes. Ketorolac can also be given by the intranasal (IN) route using a mucosal
atomization device (MAD). We aim to study the pharmacokinetics of ketorolac when
administered by the IN route using the MAD.
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children [Recruiting]
Ketorolac is an evidence-based, first-line acute migraine therapy that is commonly used in
the pediatric population; however, it is typically administered by the intravenous (IV) or
intramuscular (IM) routes, both of which require a painful and distressing needle stick to
The intranasal (IN) route is a painless and effective way of administering analgesics,
including ketorolac: IN ketorolac has been shown to be an effective analgesic in adults for
painful conditions, including acute migraine headaches. However, IN ketorolac has been
understudied in children, and it is not known how effective it is compared to IV ketorolac,
which is currently the most common way of administering ketorolac to children. If IN
ketorolac is shown to be no less effective than IV ketorolac, IN ketorolac may be a viable
and painless alternative to effectively treat acute migraine headaches in children.
Therefore, our primary aim is to demonstrate that IN ketorolac is non-inferior to IV
ketorolac for reducing pain in children with acute migraine headaches.
A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac [Enrolling by invitation]